Drug intelligence / Profile preview

allantoin + clindamycin + niacinamide

Development stage
Unknown
Lead developer
Percos
Modality
Small Molecules
Administration
Topical
01

Overview

Paknet C (also marketed as Paknet C Gel) is a topical combination dermatological formulation developed by Percos India. It contains clindamycin (1% w/w), niacinamide (nicotinamide, 4% w/w), and allantoin (0.5% w/w). Clindamycin is a lincosamide antibiotic that targets the bacterial 50S ribosomal subunit to inhibit protein synthesis and reduce populations of *Cutibacterium acnes*. Niacinamide (Vitamin B3) acts as an anti-inflammatory agent and sebum regulator, helping to reduce redness, swelling, and oil production. Allantoin serves as a skin protectant and keratolytic agent, promoting cell proliferation, soothing irritation, and aiding in skin healing and the reduction of acne scars. Paknet C is primarily indicated for the treatment of mild to moderate acne vulgaris in adults and adolescents.

Brand names
Paknet CPaknet C GelPaknet-C Gel
Other names
Allantoin + clindamycin + niacinamideAllantoin + clindamycin + nicotinamideAllantoin/clindamycin/niacinamideAllantoin/clindamycin/nicotinamide
02

Targets

HCAR2 (Hydroxycarboxylic acid receptor 2)PARP1 (Poly (adp-ribose) polymerase 1)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on allantoin + clindamycin + niacinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on allantoin + clindamycin + niacinamide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call